Publications by authors named "Lisa Meng"

Claim this Profile
H
Hospitalizations as an outcome measure in COURAGE-ALS.
Stacy A Rudnicki, Ammar Al-Chalabi, Jinsy A Andrews, Adriano Chio, Philippe Corcia, Lisa Meng

Amyotroph Lateral Scler Frontotemporal Degener· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Participant, site personnel and sponsor perspectives on decentralized trial features in COURAGE-ALS: a randomized clinical trial.
Stacy A Rudnicki, Paulos Gebrehiwet, Stuart Kupfer, Fady I Malik, Lisa Meng

Amyotroph Lateral Scler Frontotemporal Degener· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Application of the ENCALS predictive survival model in assessing the effect of the 24/44 inclusion criteria in FORTITUDE-ALS.
Tyrell Simkins Lead, Jeremy M Shefner, Stuart Kupfer, Fady I Malik, Lisa Meng

J Neuromuscul Dis· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: 48-Week Results From FOREST-HCM.
Sara Saberi, Theodore P Abraham, Lubna Choudhury, Roberto Barriales-Villa, Perry M Elliott, Lisa Meng

JACC Heart Fail· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reldesemtiv in Amyotrophic Lateral Sclerosis: Results From the COURAGE-ALS Randomized Clinical Trial.
Jeremy M Shefner, Merit E Cudkowicz, Angela Genge, Orla Hardiman, Ammar Al-Chalabi, Lisa Meng

JAMA Neurol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plasma neurofilament analysis in VITALITY-ALS.
Tyrell J Simkins, Stuart Kupfer, Fady I Malik, Lisa Meng, Stacy A Rudnicki

Amyotroph Lateral Scler Frontotemporal Degener· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aficamten vs Metoprolol for Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM Rationale, Study Design, and Baseline Characteristics.
Pablo Garcia-Pavia, Ozlem Bilen, Melissa Burroughs, Juan Pablo Costabel, Edileide de Barros Correia, Lisa Meng

JACC Heart Fail· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4.
Ahmad Masri, Mark V Sherrid, Theodore P Abraham, Lubna Choudhury, Pablo Garcia-Pavia, Lisa Meng

J Card Fail· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiac biomarkers and effects of aficamten in obstructive hypertrophic cardiomyopathy: the SEQUOIA-HCM trial.
Caroline J Coats, Ahmad Masri, Roberto Barriales-Villa, Theodore P Abraham, Douglas Marshall Brinkley, Lisa Meng

Eur Heart J· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Aficamten on Echocardiographic Cardiac Structure and Function in Symptomatic Obstructive Hypertrophic Cardiomyopathy.
Sheila M Hegde, Brian L Claggett, Xiaowen Wang, Karola Jering, Narayana Prasad, Lisa Meng

J Am Coll Cardiol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Aficamten on Cardiac Structure and Function in Obstructive Hypertrophic Cardiomyopathy: SEQUOIA-HCM CMR Substudy.
Ahmad Masri, Rhanderson N Cardoso, Theodore P Abraham, Brian L Claggett, Caroline J Coats, Lisa Meng

J Am Coll Cardiol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Aficamten on Health Status Outcomes in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM.
Charles F Sherrod, Sara Saberi, Michael E Nassif, Brian L Claggett, Caroline J Coats, Lisa Meng

J Am Coll Cardiol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aficamten and Cardiopulmonary Exercise Test Performance: A Substudy of the SEQUOIA-HCM Randomized Clinical Trial.
Matthew M Y Lee, Ahmad Masri, Michael E Nassif, Roberto Barriales-Villa, Theodore P Abraham, Lisa Meng

JAMA Cardiol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM.
Martin S Maron, Ahmad Masri, Michael E Nassif, Roberto Barriales-Villa, Theodore P Abraham, Lisa Meng

J Am Coll Cardiol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Standard-of-Care Medication Withdrawal in Patients With Obstructive Hypertrophic Cardiomyopathy Receiving Aficamten in FOREST-HCM.
Ahmad Masri, Lubna Choudhury, Roberto Barriales-Villa, Perry Elliott, Martin S Maron, Lisa Meng

J Am Coll Cardiol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of aficamten in patients with non-obstructive hypertrophic cardiomyopathy: A 36-week analysis from FOREST-HCM.
Ahmad Masri, Roberto Barriales-Villa, Perry Elliott, Michael E Nassif, Artur Oreziak, Lisa Meng

Eur J Heart Fail· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM.
Caroline J Coats, Ahmad Masri, Michael E Nassif, Roberto Barriales-Villa, Michael Arad, Lisa Meng

J Am Heart Assoc· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy.
Martin S Maron, Ahmad Masri, Michael E Nassif, Roberto Barriales-Villa, Michael Arad, Lisa Meng

N Engl J Med· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relationship between quantitative strength and functional outcomes in the phase 2 FORTITUDE-ALS trial.
Jeremy M Shefner, Bill Jacobsen, Stuart Kupfer, Fady I Malik, Lisa Meng

Amyotroph Lateral Scler Frontotemporal Degener· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exercise Capacity in Patients With Obstructive Hypertrophic Cardiomyopathy: SEQUOIA-HCM Baseline Characteristics and Study Design.
Caroline J Coats, Martin S Maron, Theodore P Abraham, Iacopo Olivotto, Matthew M Y Lee, Lisa Meng

JACC Heart Fail· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aficamten for Drug-Refractory Severe Obstructive Hypertrophic Cardiomyopathy in Patients Receiving Disopyramide: REDWOOD-HCM Cohort 3.
Anjali T Owens, Ahmad Masri, Theodore P Abraham, Lubna Choudhury, Florian Rader, Lisa Meng

J Card Fail· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
COURAGE-ALS: a randomized, double-blind phase 3 study designed to improve participant experience and increase the probability of success.
Jeremy M Shefner, Ammar Al-Chalabi, Jinsy A Andrews, Adriano Chio, Mamede De Carvalho, Lisa Meng

Amyotroph Lateral Scler Frontotemporal Degener· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health utilities and quality-adjusted life years for patients with amyotrophic lateral sclerosis receiving or placebo in FORTITUDE-ALS.
Paulos Gebrehiwet, Lisa Meng, Stacy A Rudnicki, Phil Sarocco, Jenny Wei

J Med Econ· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of omecamtiv mecarbil in heart failure with reduced ejection fraction according to N-terminal pro-B-type natriuretic peptide level: insights from the GALACTIC-HF trial.
Kieran F Docherty, John J V McMurray, Brian L Claggett, Zi Michael Miao, Kirkwood F Adams, Lisa Meng

Eur J Heart Fail· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy.
Martin S Maron, Ahmad Masri, Lubna Choudhury, Iacopo Olivotto, Sara Saberi, Lisa Meng

J Am Coll Cardiol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis